AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8037567 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow during CPB
Number of subjects: 30
Study 2524362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroxyprogesterone acetophenide 150 mg and estradiol enanthate 10 mg (DHPA/E2-EN)
Number of subjects: 50
Study 2524362 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 25 mg and estradiol cypionate 5 mg (MPA/E2-C)
Number of subjects: 50
Study 2524362 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate 50 mg and estradiol valerate 5 mg (NET-EN/E2-V)
Number of subjects: 50
Study 2524362 — intervention group
Group type: COMPARATOR
Intervention: IUD (control group)
Number of subjects: 50
Study 30093143 — intervention group
Group type: EXPERIMENTAL
Intervention: External pancreatic stents
Number of subjects: 185
Study 30093143 — intervention group
Group type: COMPARATOR
Intervention: Internal pancreatic stents
Number of subjects: 185
Study 28263039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 28263039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29566322 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection of the Cervix with Acetic acid (VIA)
Number of subjects: 1160
Study 29566322 — intervention group
Group type: COMPARATOR
Intervention: Visual Inspection of the Cervix with Lugol's Iodine (VILI)
Number of subjects: 1160
Study 29566322 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection of the Cervix with Acetic acid (VIA) among severely immuno-compromised HIV positive participants
Number of subjects: 1160
Study 29566322 — intervention group
Group type: COMPARATOR
Intervention: Visual Inspection of the Cervix with Lugol's Iodine (VILI) among severely immuno-compromised HIV positive participants
Number of subjects: 1160
Study 24708857 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAP method (dose reduction of antipsychotics)
Number of subjects: 0
Study 24708857 — intervention group
Group type: COMPARATOR
Intervention: Normal regimen (control group)
Number of subjects: 0
Study 21983797 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance exercise (70-80% of 1RM)
Number of subjects: 34
Study 21097440 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmaslyte A
Number of subjects: 60
Study 21097440 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate solution
Number of subjects: 60
Study 17667483 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual trauma-focused cognitive-behavioral therapy (CBT) for 10 weeks
Number of subjects: 24
Study 17667483 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL) for 10 weeks
Number of subjects: 24
Study 17667483 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual trauma-focused cognitive-behavioral therapy (CBT)
Number of subjects: 24
Study 16123753 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 782
Study 16123753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 782
Study 12548586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 0
Study 12548586 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged treatment with bisphosphonates
Number of subjects: 0
Study 12548586 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of bone turnover
Number of subjects: 0
Study 12548586 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates as adjuvant therapy
Number of subjects: 0
Study 12548586 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates for preventing bone loss
Number of subjects: 0
Study 10368446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt testing in children with neurocardiac syncope
Number of subjects: 0
Study 10368446 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive autonomic function tests (Valsalva, handgrip, deep breathing)
Number of subjects: 0
Study 10368446 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) measures
Number of subjects: 0
Study 8673558 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque area measurements in carotid arteries, n = 19
Number of subjects: 50
Study 8673558 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque area measurements in common carotid artery, n = 20
Number of subjects: 50
Study 8673558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intima-media thickness measurements in carotid bulb
Number of subjects: 50
Study 8673558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intima-media thickness measurements in common femoral artery
Number of subjects: 50
Study 8673558 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative measurements of plaques in femoral arteries
Number of subjects: 50
Study 1906120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol, 40-160 mg/day
Number of subjects: 40
Study 1906120 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaprilin, 80-240 mg/day
Number of subjects: 40
Study 1906120 — intervention group
Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 40
Study 6869418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning procedures
Number of subjects: 48
Study 6869418 — intervention group
Group type: COMPARATOR
Intervention: Individualistic learning procedures
Number of subjects: 48
Study 30951837 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coach-led pain self-management intervention (6 months, patient-peer coach pairs talk twice per month)
Number of subjects: 215
Study 30951837 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a class on pain and pain self-management
Number of subjects: 215
Study 30951837 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coach-led pain self-management intervention
Number of subjects: 215
Study 27838341 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy (CBT) for 9 weeks
Number of subjects: 13
Study 26672920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling Aerobic Interval Training (AIT)
Number of subjects: 45
Study 26672920 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 45
Study 26672920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 45
Study 25322754 — intervention group
Group type: EXPERIMENTAL
Intervention: NV1FGF (2.5 ml at 0.2 mg/ml or 0.4 mg/dl)
Number of subjects: 152
Study 25322754 — intervention group
Group type: EXPERIMENTAL
Intervention: NV1FGF (up to 32 mg)
Number of subjects: 152
Study 25322754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 22588946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg
Number of subjects: 110
Study 22588946 — intervention group
Group type: COMPARATOR
Intervention: Procaine hydrochloride 5 mg/kg
Number of subjects: 110
Study 19247636 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.4 g/kg
Number of subjects: 48
Study 19247636 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 48
Study 19247636 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 48
Study 19247636 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (both doses)
Number of subjects: 48
Study 16675148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tobacco PSAs
Number of subjects: 229
Study 16675148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-marijuana PSAs
Number of subjects: 229
Study 15691618 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 57
Study 15691618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg)
Number of subjects: 57
Study 15691618 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)
Number of subjects: 57
Study 15691618 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 57
Study 12095569 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic C1 whole brain external beam irradiation, 18 Gy in 2 Gy/fraction for 9 fractions
Number of subjects: 353
Study 12095569 — intervention group
Group type: COMPARATOR
Intervention: Institutions placing 1-4 patients on study
Number of subjects: 353
Study 12095569 — intervention group
Group type: COMPARATOR
Intervention: Institutions placing > or =5 patients on study
Number of subjects: 353
Study 12095569 — intervention group
Group type: COMPARATOR
Intervention: 1996-1997
Number of subjects: 353
Study 12095569 — intervention group
Group type: COMPARATOR
Intervention: 1998-2001
Number of subjects: 353
Study 10440439 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine
Number of subjects: 312
Study 10440439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 7538959 — intervention group
Group type: EXPERIMENTAL
Intervention: HES (Hydroxy‐Ethyl‐Starch) treatment
Number of subjects: 20
Study 7538959 — intervention group
Group type: COMPARATOR
Intervention: Outpatients group
Number of subjects: 20
Study 7538959 — intervention group
Group type: COMPARATOR
Intervention: Inpatients group
Number of subjects: 20
Study 2166934 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5-day therapy)
Number of subjects: 89
Study 2166934 — intervention group
Group type: COMPARATOR
Intervention: Josamycin (10-day therapy)
Number of subjects: 89
Study 7016627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyritinol 200 mg three times a day for a period of 6 weeks
Number of subjects: 270
Study 7016627 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 270
Study 30376651 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion prompt
Number of subjects: 167
Study 30376651 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 167
Study 27932570 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan/amlodipine (100/5 mg) once a day for 3 months
Number of subjects: 60
Study 27932570 — intervention group
Group type: COMPARATOR
Intervention: losartan hydrochlorothiazide (100/12.5 mg) once a day for 3 months
Number of subjects: 60
Study 27427867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice pack applied six times on the perineum for 20 minutes, reducing temperature between 10 and 15 °C)
Number of subjects: 80
Study 27427867 — intervention group
Group type: COMPARATOR
Intervention: Non-cryotherapy (water bag unable to reduce temperature significantly)
Number of subjects: 80
Study 27427867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 80
Study 27427867 — intervention group
Group type: COMPARATOR
Intervention: Non-cryotherapy
Number of subjects: 80
Study 24204594 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-taught PE program (intervention group)
Number of subjects: 708
Study 24204594 — intervention group
Group type: COMPARATOR
Intervention: Control group (generalist classroom teachers)
Number of subjects: 708
Study 21421767 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose beverage consumption to bolster self-regulatory resources
Number of subjects: 0
Study 21421767 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry rumination
Number of subjects: 0
Study 21421767 — intervention group
Group type: EXPERIMENTAL
Intervention: State rumination
Number of subjects: 0
Study 21421767 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced self-control capacity
Number of subjects: 0
Study 21421767 — intervention group
Group type: COMPARATOR
Intervention: Control condition (unpleasant task)
Number of subjects: 0
Study 18389188 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg/day
Number of subjects: 29
Study 18389188 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day plus CPA/EE (2 mg CPA/35 microg EE)
Number of subjects: 29
Study 16856548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg x kg(‐1) of rocuronium with sevoflurane
Number of subjects: 39
Study 16856548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg x kg(‐1) of rocuronium with propofol
Number of subjects: 39
Study 16856548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg x kg(‐1) of rocuronium with sevoflurane
Number of subjects: 39
Study 16856548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg x kg(‐1) of rocuronium with propofol
Number of subjects: 39
Study 16856548 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 39
Study 16856548 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 39
Study 14552083 — intervention group
Group type: EXPERIMENTAL
Intervention: QB-based Kt/V estimation
Number of subjects: 0
Study 14552083 — intervention group
Group type: EXPERIMENTAL
Intervention: QB prescribed according to patient's body weight
Number of subjects: 0
Study 10902748 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP <6 mg/liter
Number of subjects: 359
Study 10902748 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP >=25 mg/liter
Number of subjects: 359
Study 8883124 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with conjugated equine estrogen, 0.3‐0.625 mg/day for 12 months
Number of subjects: 15
Study 8883124 — intervention group
Group type: COMPARATOR
Intervention: Parathyroidectomy followed by calcitriol therapy (0.25 micrograms b.i.d. for 12 months)
Number of subjects: 15
Study 8883124 — intervention group
Group type: COMPARATOR
Intervention: Parathyroidectomy followed by calcium replacement (1 g/day for 12 months)
Number of subjects: 15
Study 1423336 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. levodopa
Number of subjects: 0
Study 1423336 — intervention group
Group type: COMPARATOR
Intervention: Phenylalanine (LNAA)
Number of subjects: 0
Study 3159318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal skin testing with tubocurarine and atracurium (diluted 1 in 1,000)
Number of subjects: 22
Study 3159318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia using atracurium or tubocurarine
Number of subjects: 22
Study 3159318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal skin testing
Number of subjects: 22
Study 30661698 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D3 orally/month for 6 months
Number of subjects: 83
Study 30661698 — intervention group
Group type: COMPARATOR
Intervention: AED without vitamin D3
Number of subjects: 83
Study 29642282 — intervention group
Group type: EXPERIMENTAL
Intervention: N6022 (5 mg)
Number of subjects: 14
Study 29642282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 26983754 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection (XBJ)
Number of subjects: 700
Study 26983754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 24614628 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 40
Study 22190621 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing a clockwise force field (CWFF)
Number of subjects: 0
Study 22190621 — intervention group
Group type: COMPARATOR
Intervention: Observing a counter-clockwise force field (CCWFF)
Number of subjects: 0
Study 19240085 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ, 10-20 mg/day)
Number of subjects: 346
Study 19240085 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine (QUE, 300-700 mg/day)
Number of subjects: 346
Study 19240085 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 346
Study 19240085 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine (QUE)
Number of subjects: 346
Study 18619511 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically heated cigarette smoking system (EHCSS, Series K)
Number of subjects: 90
Study 18619511 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarette (CC)
Number of subjects: 90
Study 17561988 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilarginine (a non‐specific inhibitor of nitric oxide synthase)
Number of subjects: 0
Study 17561988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15486802 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P, n = 50)
Number of subjects: 100
Study 15486802 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (group M, n = 50)
Number of subjects: 100
Study 11244226 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1% gel
Number of subjects: 44
Study 11244226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10756746 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (group B), given in one dose
Number of subjects: 182
Study 10756746 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 182
Study 8304056 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin bolus injection followed by continuous infusion
Number of subjects: 0
Study 8304056 — intervention group
Group type: COMPARATOR
Intervention: Periods of hypoxia (17% oxygen) and hypercapnia (2‐4% CO2)
Number of subjects: 0
Study 3731679 — intervention group
Group type: EXPERIMENTAL
Intervention: amiflamine, 5 mg bid (n = 8)
Number of subjects: 12
Study 3731679 — intervention group
Group type: COMPARATOR
Intervention: placebo, 1 capsule twice a day (n = 4)
Number of subjects: 12
Study 3731679 — intervention group
Group type: EXPERIMENTAL
Intervention: oral tyramine (400 mg)
Number of subjects: 12
Study 30791040 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (≥60 s)
Number of subjects: 265
Study 30791040 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (<10 s)
Number of subjects: 265
Study 29778773 — intervention group
Group type: EXPERIMENTAL
Intervention: 100PG liquid
Number of subjects: 30
Study 29778773 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-based liquids (2PG:98VG, 20PG:80VG, 55PG:45VG)
Number of subjects: 30
Study 29778773 — intervention group
Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 30
Study 27338467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling to increase fruit intake (+1 serving/day; 150 g/day)
Number of subjects: 109
Study 27338467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling to increase dairy intake (+1 serving/day; 200-250 g/day)
Number of subjects: 109
Study 27338467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling to increase vegetable intake (+2 servings/day; 150 g/day)
Number of subjects: 109
Study 27338467 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 109
Study 27338467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (dietary counselling)
Number of subjects: 109
Study 27338467 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 109
Study 25006720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (rectal temperature of 33 to 34°C for 72 hours within 6 hours after birth)
Number of subjects: 325
Study 25006720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 325
Study 25006720 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care alone)
Number of subjects: 325
Study 25006720 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 325
Study 21543653 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 88
Study 21543653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 21543653 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NGAL
Number of subjects: 88
Study 21543653 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cystatin C
Number of subjects: 88
Study 19339053 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 38
Study 19339053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16807260 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter-only (A2)
Number of subjects: 40
Study 16807260 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-only (A3)
Number of subjects: 40
Study 16807260 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter and SP (A4)
Number of subjects: 40
Study 16807260 — intervention group
Group type: COMPARATOR
Intervention: No filter, no SP (A1)
Number of subjects: 40
Study 15301918 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (0, 0.5, 1, and 2 mg/70 kg)
Number of subjects: 16
Study 15301918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water stimulus (2 degrees C) during butorphanol administration
Number of subjects: 16
Study 15301918 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study 12174334 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg daily for 21 days)
Number of subjects: 16
Study 10503166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan 2 mg i.v. once a week for eight weeks
Number of subjects: 98
Study 10503166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan 5 mg i.v. once a week for eight weeks
Number of subjects: 98
Study 10503166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan 10 mg i.v. once a week for eight weeks
Number of subjects: 98
Study 10503166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan 1 mg i.v. twice a week for 12 weeks
Number of subjects: 98
Study 10503166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan 5 mg i.v. twice a week for 12 weeks
Number of subjects: 98
Study 10503166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle containing mannitol plus dextran 40) i.v. twice a week for 12 weeks
Number of subjects: 98
Study 10503166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan in combination with didanosine (ddI)
Number of subjects: 98
Study 10503166 — intervention group
Group type: COMPARATOR
Intervention: Didanosine (ddI) alone
Number of subjects: 98
Study 7521940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (1 mg-2 mg intravenously)
Number of subjects: 88
Study 7521940 — intervention group
Group type: COMPARATOR
Intervention: Dextran 40,000 (standard therapy)
Number of subjects: 88
Study 2519936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (1.5 mg/kg)
Number of subjects: 21
Study 2519936 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 21
Study 31014423 — intervention group
Group type: EXPERIMENTAL
Intervention: calsurf treatment + conventional treatment
Number of subjects: 208